We analyzed the effect of @entity2936 triggering on the @entity3118 -induced apoptosis of B @entity1072 (B- @entity1072 ) cells. Peripheral blood samples obtained from 15 @entity1 were incubated with @entity3118 in the absence or the presence of the anti- @entity2936 monoclonal antibody (MoAb) G28-5. In 12 @entity1 a significant proportion of apoptotic cells, ranging from 22% to 38% (mean +/- SE: 28.5 +/- 1.6), were detected after 3 days of culture. In 9 of these samples, the addition of G28-5 reduced apoptosis by at least 30.1% and by 57.1% +/- 7.8% on average (P = .0077). Because the @entity2936 antigen activates @entity2451 / @entity4632 transcription factors in B cells, and @entity2451 / @entity4632 complexes can inhibit cell apoptosis, we investigated whether the antiapoptotic effect of G28-5, in our system, could be related to modulation of @entity2451 / @entity4632 activity. As expected, B- @entity1072 cells displayed significant levels of nuclear @entity2451 / @entity4632 activity; @entity2451 , @entity9135 , and @entity4632 components of the @entity2451 / @entity4632 protein family were identified in these complexes. After exposure to @entity3118 , @entity2451 / @entity4632 complexes were decreased in the nuclei. The addition of G28-5 upregulated the @entity2451 / @entity4632 levels. To determine the involvement of @entity2451 / @entity4632 activity in the G28-5-mediated inhibition of apoptosis, we blocked the transcription factor with a decoy oligonucleotide, corresponding to the @entity2451 / @entity4632 consensus sequence. Cells incubated with the anti- @entity2936 MoAb in the presence of the decoy oligonucleotide but not a control oligonucleotide displayed a complete impairment of the G28-5 antiapoptotic effect, indicating that @entity2451 / @entity4632 activity was required for the inhibition of apoptosis. These results suggest that @entity2936 triggering in vivo could counteract the apoptotic effect of @entity3118 on B- @entity1072 cells and that its neutralization, or the use of @entity2451 / @entity4632 inhibitors, could improve the therapeutic effect of @entity3118 .

Triggering of XXXX antigen inhibits @entity3118 -induced apoptosis in B @entity1072 cells.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9135 :: ('5970', 'Gene') :: ['RelA'] @entity2451 :: ('4790', 'Gene') :: ['p50', 'NF-kappaB'] @entity2936 :: ('958', 'Gene') :: ['CD40'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'chronic lymphocytic leukemia'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity4632 :: ('5966', 'Gene') :: ['Rel', 'c-Rel']
@entity2936 :: (958,Gene) :: ['CD40']
